INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 135 filers reported holding INTRA CELLULAR THERAPIES INC in Q4 2018. The put-call ratio across all filers is 0.27 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $2,153,874 | +2424.3% | 31,448 | +2450.5% | 0.40% | +2270.6% |
| Q1 2024 | $85,324 | -31.1% | 1,233 | -28.7% | 0.02% | -29.2% |
| Q4 2023 | $123,831 | +12.7% | 1,729 | -18.0% | 0.02% | +33.3% |
| Q3 2023 | $109,858 | -18.5% | 2,109 | -0.9% | 0.02% | -5.3% |
| Q2 2023 | $134,808 | +16.9% | 2,129 | 0.0% | 0.02% | +11.8% |
| Q1 2023 | $115,285 | +101027.2% | 2,129 | -1.2% | 0.02% | -5.6% |
| Q4 2022 | $114 | -100.0% | 2,155 | -93.5% | 0.02% | -78.8% |
| Q3 2018 | $724,000 | +28.1% | 33,384 | +4.3% | 0.08% | +19.7% |
| Q2 2018 | $565,000 | -2.2% | 32,000 | +16.6% | 0.07% | -6.6% |
| Q1 2018 | $578,000 | -55.1% | 27,443 | -67.5% | 0.08% | -63.3% |
| Q3 2016 | $1,288,000 | +100.9% | 84,488 | +411.3% | 0.21% | +93.5% |
| Q2 2016 | $641,000 | +25.0% | 16,524 | -10.5% | 0.11% | +21.6% |
| Q1 2016 | $513,000 | – | 18,457 | – | 0.09% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DCF Advisers, LLC | 375,000 | $15,308,000 | 5.42% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 113,258 | $4,623,000 | 2.06% |
| Tri Locum Partners LP | 150,783 | $6,155,000 | 2.02% |
| COOPER/HAIMS ADVISORS, LLC | 61,116 | $2,495,000 | 1.64% |
| Vantage Consulting Group Inc | 226,670 | $9,252,000 | 1.61% |
| Nicholas Investment Partners, LP | 598,261 | $24,421,000 | 1.53% |
| Bellevue Group AG | 3,609,919 | $147,357,000 | 1.44% |
| GENERAL AMERICAN INVESTORS CO INC | 350,804 | $14,320,000 | 1.20% |
| Rhenman & Partners Asset Management AB | 429,728 | $17,541,000 | 1.19% |
| WASATCH ADVISORS LP | 6,506,789 | $265,607,000 | 1.08% |